Al Hammadi 9M 2023 profit rises 29% to SAR 238.1 mln, Q3 at SAR 74.9 mln

05/11/2023 Argaam Exclusive

View other reports

Al Hammadi Holding reported a net profit of SAR 238.1 million in 9M 2023, a rise of 29% from SAR 184.2 million in the year-earlier period, as revenues grew 12% year-on-year (YoY) to SAR 873.1 million on improved topline of medical services and pharmaceutical segments.

Financials (M)

Item	9m 2022	9m 2023	Change‬
Revenues	779.75	873.08	12.0 %
Gross Income	288.67	326.70	13.2 %
Operating Income	187.51	254.07	35.5 %
Net Income	184.17	238.14	29.3 %
Average Shares	160.00	160.00	-
EPS (Riyals)	1.15	1.49	29.3 %

Expected credit loss provision, which booked a net credit loss reversal of SAR 6.3 million during the nine-month period as the company continued improving collection rates.

Current Quarter Comparison (M)

Compared With The

Item	Q3 2022	Q3 2023	Change‬
Revenues	246.92	297.83	20.6 %
Gross Income	83.50	113.08	35.4 %
Operating Income	52.33	79.30	51.5 %
Net Income	57.11	74.87	31.1 %
Average Shares	160.00	160.00	-
EPS (Riyals)	0.36	0.47	31.1 %

Item	Q2 2023	Q3 2023	Change‬
Revenues	276.66	297.83	7.7 %
Gross Income	93.42	113.08	21.0 %
Operating Income	87.53	79.30	(9.4 %)
Net Income	81.85	74.87	(8.5 %)
Average Shares	160.00	160.00	-
EPS (Riyals)	0.51	0.47	(8.5 %)

Q3 2023 net profit jumped 31% YoY to SAR 74.9 million on solid revenue growth of 20.6% YoY, along with improved cost efficiencies where gross profit and operating profit margins improved by 4.1 percentage points and 2.3 percentage points, respectively. Expected credit loss provision declined to SAR 5.6 million from SAR 11.3 million in Q3 2022.

Sequentially, Q3 net profit fell 8.5% from SAR 81.85 million in Q2 2023.

Shareholders’ equity, no minority interest, increased to SAR 1.83 billion as of Sept. 30, 2023, from SAR 1.69 billion a year earlier.

View more financial results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2014	122.04	16.4 %	54.71	15.6 %	35.96	19.5 %
Q2 2014	121.66	11.8 %	53.68	17.1 %	35.77	57.3 %
Q3 2014	108.83	13.1 %	44.74	21.5 %	24.77	30.3 %
Q4 2014	129.43	4.3 %	55.99	1.5 %	34.52	0.5 %
2014	481.96	11.0 %	209.11	12.9 %	130.95	16.8 %
Q1 2015	129.48	6.1 %	50.64	(7.4 %)	33.35	(7.3 %)
Q2 2015	137.36	12.9 %	63.56	18.4 %	37.91	6.0 %
Q3 2015	136.80	25.7 %	57.97	29.6 %	31.92	28.8 %
Q4 2015	157.70	21.8 %	68.06	21.6 %	40.39	17.0 %
2015	561.33	16.5 %	240.24	14.9 %	143.57	9.6 %
Q1 2016	144.16	11.3 %	54.75	8.1 %	26.66	(20.0 %)
Q2 2016	138.08	0.5 %	57.56	(9.5 %)	27.63	(27.1 %)
Q3 2016	141.35	3.3 %	56.48	(2.6 %)	25.97	(18.6 %)
Q4 2016	182.65	15.8 %	73.35	7.8 %	18.58	(54.0 %)
2016	606.24	8.0 %	242.13	0.8 %	98.81	(31.2 %)
Q1 2017	180.23	25.0 %	62.02	13.3 %	33.61	26.0 %
Q2 2017	176.71	28.0 %	58.16	1.0 %	32.88	19.0 %
Q3 2017	163.01	15.3 %	53.91	(4.5 %)	26.46	1.9 %
Q4 2017	188.69	3.3 %	65.08	(11.3 %)	33.93	82.6 %
2017	708.62	16.9 %	239.16	(1.2 %)	126.88	28.4 %
Q1 2018	200.67	11.3 %	66.84	7.8 %	38.29	13.9 %
Q2 2018	214.49	21.4 %	53.28	(8.4 %)	28.26	(14.0 %)
Q3 2018	250.40	53.6 %	64.92	20.4 %	31.19	17.9 %
Q4 2018	228.04	20.9 %	65.32	0.4 %	29.53	(13.0 %)
2018	893.60	26.1 %	250.36	4.7 %	127.27	0.3 %
Q1 2019	229.68	14.5 %	65.60	(1.9 %)	27.20	(29.0 %)
Q2 2019	253.83	18.3 %	71.08	33.4 %	30.95	9.5 %
Q3 2019	220.00	(12.1 %)	62.22	(4.2 %)	31.85	2.1 %
Q4 2019	270.55	18.6 %	83.72	28.2 %	39.60	34.1 %
2019	974.06	9.0 %	282.62	12.9 %	129.59	1.8 %
Q1 2020	206.69	(10.0 %)	66.48	1.3 %	33.84	24.4 %
Q2 2020	244.30	(3.8 %)	90.81	27.7 %	53.15	71.8 %
Q3 2020	207.85	(5.5 %)	77.59	24.7 %	43.13	35.4 %
Q4 2020	230.47	(14.8 %)	68.48	(18.2 %)	19.33	(51.2 %)
2020	764.06	(21.6 %)	252.83	(10.5 %)	103.91	(19.8 %)
Q1 2021	226.29	9.5 %	87.41	31.5 %	22.69	(32.9 %)
Q2 2021	223.90	(8.4 %)	79.96	(11.9 %)	33.63	(36.7 %)
Q3 2021	219.92	5.8 %	88.16	13.6 %	49.65	15.1 %
Q4 2021	281.78	22.3 %	108.53	58.5 %	19.27	(0.3 %)
2021	951.89	24.6 %	364.05	44.0 %	125.24	20.5 %
Q1 2022	250.89	10.9 %	96.08	9.9 %	65.16	187.1 %
Q2 2022	281.94	25.9 %	109.09	36.4 %	70.02	108.2 %
Q3 2022	246.92	12.3 %	83.50	(5.3 %)	52.33	5.4 %
Q4 2022	342.64	21.6 %	131.00	20.7 %	75.30	290.7 %
2022	1,122.40	17.9 %	419.67	15.3 %	262.81	109.8 %
Q1 2023	298.60	19.0 %	120.20	25.1 %	87.24	33.9 %
Q2 2023	276.66	(1.9 %)	93.42	(14.4 %)	87.53	25.0 %
Q3 2023	297.83	20.6 %	113.08	35.4 %	79.30	51.5 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2013	434.08	14.6 %	185.16	13.5 %	112.10	21.4 %
2014	481.96	11.0 %	209.11	12.9 %	130.95	16.8 %
2015	561.33	16.5 %	240.24	14.9 %	143.57	9.6 %
2016	606.24	8.0 %	242.13	0.8 %	98.81	(31.2 %)
2017	708.62	16.9 %	239.16	(1.2 %)	126.88	28.4 %
2018	893.60	26.1 %	250.36	4.7 %	127.27	0.3 %
2019	974.06	9.0 %	282.62	12.9 %	129.59	1.8 %
2020	764.06	(21.6 %)	252.83	(10.5 %)	103.91	(19.8 %)
2021	951.89	24.6 %	364.05	44.0 %	125.24	20.5 %
2022	1,122.40	17.9 %	419.67	15.3 %	262.81	109.8 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2014	34.23	14.7 %	0.21	-	34.23	0.21
Q2 2014	35.60	18.4 %	0.22	-	35.60	0.22
Q3 2014	25.42	38.7 %	0.16	-	25.42	0.16
Q4 2014	33.71	1.2 %	0.21	-	33.71	0.21
2014	128.95	15.6 %	0.81	-	128.95	0.81
Q1 2015	41.01	19.8 %	0.26	9.80	31.21	0.20
Q2 2015	36.89	3.6 %	0.23	-	36.89	0.23
Q3 2015	27.69	8.9 %	0.17	-	27.69	0.17
Q4 2015	35.75	6.0 %	0.22	-	35.75	0.22
2015	141.33	9.6 %	0.88	9.80	131.53	0.82
Q1 2016	21.14	(48.5 %)	0.13	-	21.14	0.13
Q2 2016	20.63	(44.1 %)	0.13	-	20.63	0.13
Q3 2016	20.73	(25.1 %)	0.13	-	20.73	0.13
Q4 2016	10.48	(70.7 %)	0.07	-	10.48	0.07
2016	72.96	(48.4 %)	0.46	-	72.96	0.46
Q1 2017	27.97	32.3 %	0.17	-	27.97	0.17
Q2 2017	25.66	24.4 %	0.16	-	25.66	0.16
Q3 2017	23.59	13.8 %	0.15	-	23.59	0.15
Q4 2017	30.76	193.4 %	0.19	-	30.76	0.19
2017	107.97	48.0 %	0.67	-	107.97	0.67
Q1 2018	30.88	10.4 %	0.19	-	30.88	0.19
Q2 2018	19.93	(22.3 %)	0.12	-	19.93	0.12
Q3 2018	21.31	(9.7 %)	0.13	-	21.31	0.13
Q4 2018	17.70	(42.5 %)	0.11	-	17.70	0.11
2018	89.81	(16.8 %)	0.56	-	89.81	0.56
Q1 2019	24.17	(21.7 %)	0.15	-	24.17	0.15
Q2 2019	20.01	0.4 %	0.13	-	20.01	0.13
Q3 2019	21.17	(0.6 %)	0.13	-	21.17	0.13
Q4 2019	27.65	56.2 %	0.17	-	27.65	0.17
2019	93.00	3.5 %	0.58	-	93.00	0.58
Q1 2020	24.94	3.2 %	0.16	-	24.94	0.16
Q2 2020	39.10	95.4 %	0.24	(4.99)	44.10	0.28
Q3 2020	36.57	72.7 %	0.23	-	36.57	0.23
Q4 2020	30.21	9.3 %	0.19	-	30.21	0.19
2020	130.83	40.7 %	0.82	(4.99)	135.82	0.85
Q1 2021	35.54	42.5 %	0.22	-	35.54	0.22
Q2 2021	40.31	3.1 %	0.25	-	40.31	0.25
Q3 2021	3.58	(90.2 %)	0.02	(39.18)	42.76	0.27
Q4 2021	10.67	(64.7 %)	0.07	(9.69)	20.36	0.13
2021	90.09	(31.1 %)	0.56	(48.87)	138.96	0.87
Q1 2022	61.96	74.4 %	0.39	-	61.96	0.39
Q2 2022	65.10	61.5 %	0.41	-	65.10	0.41
Q3 2022	57.11	1494.9 %	0.36	-	57.11	0.36
Q4 2022	73.17	586.0 %	0.46	-	73.17	0.46
2022	257.34	185.6 %	1.61	-	257.34	1.61
Q1 2023	81.42	31.4 %	0.51	-	81.42	0.51
Q2 2023	81.85	25.7 %	0.51	-	81.85	0.51
Q3 2023	74.87	31.1 %	0.47	-	74.87	0.47

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2013	111.50	18.3 %	0.70	-	111.50	0.70
2014	128.95	15.6 %	0.81	-	128.95	0.81
2015	141.33	9.6 %	0.88	9.80	131.53	0.82
2016	72.96	(48.4 %)	0.46	-	72.96	0.46
2017	107.97	48.0 %	0.67	-	107.97	0.67
2018	89.81	(16.8 %)	0.56	-	89.81	0.56
2019	93.00	3.5 %	0.58	-	93.00	0.58
2020	130.83	40.7 %	0.82	(4.99)	135.82	0.85
2021	90.09	(31.1 %)	0.56	(48.87)	138.96	0.87
2022	257.34	185.6 %	1.61	-	257.34	1.61

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	42.66 %	27.85 %	24.35 %
Q2 2014	43.18 %	29.90 %	26.17 %
Q3 2014	43.70 %	30.34 %	26.97 %
Q4 2014	43.39 %	30.09 %	26.75 %
2014	43.39 %	30.07 %	26.75 %
Q1 2015	41.90 %	29.13 %	25.73 %
Q2 2015	42.55 %	28.68 %	25.19 %
Q3 2015	42.80 %	29.71 %	24.29 %
Q4 2015	42.80 %	31.06 %	23.43 %
2015	42.80 %	31.06 %	23.43 %
Q1 2016	42.42 %	30.79 %	21.09 %
Q2 2016	41.32 %	30.64 %	18.24 %
Q3 2016	40.74 %	29.96 %	16.90 %
Q4 2016	39.94 %	25.11 %	12.04 %
2016	39.94 %	25.10 %	12.03 %
Q1 2017	38.83 %	24.74 %	12.43 %
Q2 2017	36.71 %	24.09 %	12.46 %
Q3 2017	35.22 %	23.41 %	12.48 %
Q4 2017	33.75 %	25.39 %	15.24 %
2017	33.75 %	25.39 %	15.24 %
Q1 2018	33.46 %	26.03 %	15.21 %
Q2 2018	31.18 %	25.45 %	13.71 %
Q3 2018	29.28 %	24.60 %	12.04 %
Q4 2018	28.02 %	24.14 %	10.05 %
2018	28.02 %	24.14 %	10.05 %
Q1 2019	27.00 %	22.96 %	9.01 %
Q2 2019	27.75 %	22.56 %	8.65 %
Q3 2019	28.36 %	23.59 %	8.92 %
Q4 2019	29.01 %	23.82 %	9.55 %
2019	29.01 %	23.82 %	9.55 %
Q1 2020	29.81 %	25.12 %	9.86 %
Q2 2020	32.21 %	27.70 %	12.52 %
Q3 2020	34.28 %	29.29 %	14.34 %
Q4 2020	34.11 %	28.49 %	15.27 %
2020	33.09 %	27.20 %	17.78 %
Q1 2021	35.68 %	26.87 %	16.11 %
Q2 2021	35.28 %	25.58 %	16.05 %
Q3 2021	35.98 %	26.21 %	16.52 %
Q4 2021	38.24 %	24.65 %	14.60 %
2021	38.24 %	24.65 %	14.60 %
Q1 2022	38.17 %	28.20 %	16.94 %
Q2 2022	38.84 %	29.87 %	18.38 %
Q3 2022	37.42 %	29.18 %	19.27 %
Q4 2022	37.39 %	32.36 %	22.93 %
2022	37.39 %	32.36 %	22.93 %
Q1 2023	37.93 %	32.83 %	23.66 %
Q2 2023	36.75 %	34.47 %	25.20 %
Q3 2023	37.65 %	35.21 %	25.61 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2013	42.66 %	28.96 %	25.69 %
2014	43.39 %	30.07 %	26.75 %
2015	42.80 %	31.06 %	23.43 %
2016	39.94 %	25.10 %	12.03 %
2017	33.75 %	25.39 %	15.24 %
2018	28.02 %	24.14 %	10.05 %
2019	29.01 %	23.82 %	9.55 %
2020	33.09 %	27.20 %	17.78 %
2021	38.24 %	24.65 %	14.60 %
2022	37.39 %	32.36 %	22.93 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	44.83 %	32.21 %	28.04 %
Q2 2014	44.12 %	32.25 %	29.26 %
Q3 2014	41.11 %	26.05 %	23.36 %
Q4 2014	43.26 %	29.45 %	26.04 %
Q1 2015	39.11 %	28.49 %	24.10 %
Q2 2015	46.28 %	30.21 %	26.86 %
Q3 2015	42.37 %	30.62 %	20.24 %
Q4 2015	43.16 %	34.31 %	22.67 %
Q1 2016	37.98 %	27.65 %	14.66 %
Q2 2016	41.68 %	29.60 %	14.94 %
Q3 2016	39.95 %	27.83 %	14.67 %
Q4 2016	40.16 %	17.59 %	5.74 %
Q1 2017	34.41 %	25.82 %	15.52 %
Q2 2017	32.91 %	26.06 %	14.52 %
Q3 2017	33.07 %	24.41 %	14.47 %
Q4 2017	34.49 %	25.21 %	16.30 %
Q1 2018	33.31 %	28.10 %	15.39 %
Q2 2018	24.84 %	23.98 %	9.29 %
Q3 2018	25.93 %	21.86 %	8.51 %
Q4 2018	28.65 %	23.30 %	7.76 %
Q1 2019	28.56 %	22.87 %	10.52 %
Q2 2019	28.00 %	22.30 %	7.88 %
Q3 2019	28.28 %	26.14 %	9.62 %
Q4 2019	30.94 %	24.16 %	10.22 %
Q1 2020	32.17 %	28.77 %	12.07 %
Q2 2020	37.17 %	32.12 %	18.05 %
Q3 2020	37.33 %	33.16 %	17.59 %
Q4 2020	29.72 %	20.18 %	13.11 %
Q1 2021	38.63 %	22.24 %	15.70 %
Q2 2021	35.71 %	27.50 %	18.00 %
Q3 2021	40.09 %	35.31 %	19.45 %
Q4 2021	38.51 %	16.01 %	7.22 %
Q1 2022	38.29 %	36.27 %	24.70 %
Q2 2022	38.69 %	33.79 %	23.09 %
Q3 2022	33.82 %	31.75 %	23.13 %
Q4 2022	38.23 %	28.77 %	21.35 %
Q1 2023	40.25 %	37.48 %	27.27 %
Q2 2023	33.77 %	40.70 %	29.58 %
Q3 2023	37.97 %	35.24 %	25.14 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2014	160.00	0.72	0.69	3.87
Q2 2014	160.00	0.76	0.76	7.88
Q3 2014	160.00	0.80	0.80	8.04
Q4 2014	160.00	0.81	0.81	8.25
Q1 2015	160.00	0.85	0.79	8.51
Q2 2015	160.00	0.86	0.80	8.27
Q3 2015	160.00	0.87	0.81	8.44
Q4 2015	160.00	0.88	0.82	8.66
Q1 2016	160.00	0.76	0.76	8.80
Q2 2016	160.00	0.66	0.66	8.37
Q3 2016	160.00	0.61	0.61	8.50
Q4 2016	160.00	0.46	0.46	8.56
Q1 2017	160.00	0.50	0.50	8.75
Q2 2017	160.00	0.53	0.53	8.89
Q3 2017	160.00	0.55	0.55	9.04
Q4 2017	160.00	0.67	0.67	8.67
Q1 2018	160.00	0.69	0.69	8.85
Q2 2018	160.00	0.66	0.66	8.98
Q3 2018	160.00	0.64	0.64	9.11
Q4 2018	160.00	0.56	0.56	9.24
Q1 2019	160.00	0.52	0.52	9.40
Q2 2019	160.00	0.52	0.52	9.51
Q3 2019	160.00	0.52	0.52	9.63
Q4 2019	160.00	0.58	0.58	9.79
Q1 2020	160.00	0.59	0.59	9.95
Q2 2020	160.00	0.71	0.74	10.21
Q3 2020	160.00	0.80	0.83	10.42
Q4 2020	160.00	0.82	0.85	10.62
Q1 2021	160.00	0.88	0.92	10.47
Q2 2021	160.00	0.89	0.89	10.73
Q3 2021	160.00	0.69	0.93	10.75
Q4 2021	160.00	0.56	0.87	10.37
Q1 2022	160.00	0.73	1.03	10.47
Q2 2022	160.00	0.88	1.19	10.56
Q3 2022	160.00	1.22	1.28	10.61
Q4 2022	160.00	1.61	1.61	10.69
Q1 2023	160.00	1.73	1.73	10.85
Q2 2023	160.00	1.83	1.83	11.01
Q3 2023	160.00	1.95	1.95	11.49

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2013	160.00	0.70	0.70	3.66
2014	160.00	0.81	0.81	8.25
2015	160.00	0.88	0.82	8.66
2016	160.00	0.46	0.46	8.56
2017	160.00	0.67	0.67	8.67
2018	160.00	0.56	0.56	9.24
2019	160.00	0.58	0.58	9.79
2020	160.00	0.82	0.85	10.62
2021	160.00	0.56	0.87	10.37
2022	160.00	1.61	1.61	10.69

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	51.42	51.42	5.14
Q4 2014	48.92	48.92	4.78
Q1 2015	51.53	55.54	5.14
Q2 2015	54.13	58.30	5.61
Q3 2015	44.33	47.69	4.57
Q4 2015	41.63	44.73	4.24
Q1 2016	36.41	36.41	3.14
Q2 2016	45.86	45.86	3.60
Q3 2016	36.32	36.32	2.62
Q4 2016	68.31	68.31	3.64
Q1 2017	61.37	61.37	3.50
Q2 2017	58.51	58.51	3.49
Q3 2017	47.94	47.94	2.91
Q4 2017	41.25	41.25	3.21
Q1 2018	39.28	39.28	3.07
Q2 2018	37.68	37.68	2.76
Q3 2018	32.21	32.21	2.27
Q4 2018	33.55	33.55	2.04
Q1 2019	35.91	35.91	1.98
Q2 2019	30.97	30.97	1.69
Q3 2019	32.09	32.09	1.73
Q4 2019	27.16	27.16	1.61
Q1 2020	24.17	24.17	1.42
Q2 2020	23.40	22.41	1.62
Q3 2020	27.10	26.08	2.08
Q4 2020	26.52	25.54	2.04
Q1 2021	24.66	23.82	2.08
Q2 2021	33.33	33.33	2.77
Q3 2021	42.10	31.02	2.68
Q4 2021	53.70	34.82	2.92
Q1 2022	46.73	32.92	3.25
Q2 2022	41.33	30.71	3.46
Q3 2022	36.83	35.09	4.23
Q4 2022	24.93	24.93	3.75
Q1 2023	28.18	28.18	4.49
Q2 2023	33.19	33.19	5.53
Q3 2023	26.78	26.78	4.53

Period	P/E	Adjusted P/E	Price/book
2013	-	-	-
2014	48.92	48.92	4.78
2015	41.63	44.73	4.24
2016	68.34	68.34	3.64
2017	41.25	41.25	3.21
2018	33.55	33.55	2.04
2019	27.16	27.16	1.61
2020	26.52	25.54	2.04
2021	53.70	34.82	2.92
2022	24.93	24.93	3.75

Business Segments (Million)

Compared With The

Period	healthy services and other	Pharmaceutical sales revenue - Pharmacies
Q1 2017	150.74	29.49
Q2 2017	147.45	29.26
Q3 2017	136.70	26.31
Q4 2017	155.95	32.73
Q1 2018	140.85	59.82
Q2 2018	143.64	71.39
Q3 2018	140.83	109.03
Q4 2018	154.81	73.23
Q1 2019	146.91	82.77
Q2 2019	151.05	102.78
Q3 2019	149.00	71.00
Q4 2019	177.92	92.62
Q1 2020	152.48	54.21
Q2 2020	192.83	51.46
Q3 2020	47.34	35.26
Q4 2020	185.43	45.04
Q1 2021	168.82	57.47
Q2 2021	163.87	60.02
Q3 2021	180.27	39.64
Q4 2021	224.93	56.85
Q1 2022	195.39	55.50
Q2 2022	232.25	49.69
Q3 2022	201.88	45.04
Q4 2022	241.22	101.43
Q1 2023	238.75	59.85
Q2 2023	217.85	58.80
Q3 2023	242.76	55.06

Period	healthy services and other	Pharmaceutical sales revenue - Pharmacies
2013	317.00	117.11
2014	360.30	121.61
2015	451.60	109.71
2016	552.40	89.11
2017	590.84	117.78
2018	580.13	313.47
2019	624.88	349.18
2020	578.09	185.97
2021	737.90	213.99
2022	870.74	251.65

Analysts Estimates (Million)

Item	Q3 2023 (e)	Q3 2023 (a)	Change‬
Average	68.60	74.87	9.15 %

Estimates vs Actual (Million)

Item	Q3 2023 (e)	Q3 2023 (a)	Change
OSOOL AND BAKHEET	78.59	74.87	(4.7) %
Al Rajhi Capital	84.00	74.87	(10.9) %
AlJazira Capital	62.10	74.87	20.6 %
SNB Capital	60.20	74.87	24.4 %
U-Capital	58.10	74.87	28.9 %

Financial Ratios

	Current
Market Cap (M Riyal)	6,144.00
Enterprise Value (EV) (M)	5,905.92
Shares Outstanding ((M))	160.00
EPS ( Riyal) (TTM)	2.04
Book Value (BV) ( Riyal)	12.11
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	23.23
P/E (TTM)	18.83
Price/book	3.17
Return on Average Assets (%) (TTM)	12.5
Return on Average Equity (%) (TTM)	17.3

Al Hammadi Holding (ALHAMMADI)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Al Hammadi 9M 2023 profit rises 29% to SAR 238.1 mln, Q3 at SAR 74.9 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2023 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Al Hammadi Holding (ALHAMMADI)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Al Hammadi 9M 2023 profit rises 29% to SAR 238.1 mln, Q3 at SAR 74.9 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q3 2023

Revenue by Business Segment (Latest) 2023 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Al Hammadi Holding (ALHAMMADI)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)